These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19770692)

  • 1. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
    Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
    Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
    Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
    J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 IgA specific serum antibodies and disease progression during HIV-1 infection.
    Margalith M; Levy E; Rinaldo CR; Detels R; Phair J; Kaslow R; Saah AJ; Sarov B
    J Hum Virol; 2001; 4(5):269-77. PubMed ID: 11907384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
    Jülg B; Goebel FD
    Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
    Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
    Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
    Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
    Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.